Investor Outlook: Rising from the Ashes; GSK's European Approval of Strimvelis for ADA-SCID
- PMID: 27267267
- DOI: 10.1089/humc.2016.29010.ind
Investor Outlook: Rising from the Ashes; GSK's European Approval of Strimvelis for ADA-SCID
Abstract
GlaxoSmithKline's (GSK) and partner San Raffaele Telethon Institute for Gene Therapy's recent positive European approval for Strimvelis for treatment of severe combined immunodeficiency due to adenosine deaminase deficiency (ADA-SCID) represents the second EU-approved gene therapy and the first γ-retrovirus and first ex vivo gene therapy. In this article we discuss the significance and implications of this historic approval for the broader gene therapy field.
Comment in
-
Patient-driven search for rare disease therapies: the Fondazione Telethon success story and the strategy leading to Strimvelis.EMBO Mol Med. 2017 Mar;9(3):289-292. doi: 10.15252/emmm.201607293. EMBO Mol Med. 2017. PMID: 28148554 Free PMC article.
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
